Literature DB >> 15131245

SR147778 [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization.

Murielle Rinaldi-Carmona1, Francis Barth, Christian Congy, Serge Martinez, Didier Oustric, Alain Pério, Martine Poncelet, Jeanne Maruani, Michèle Arnone, Olivier Finance, Philippe Soubrié, Gérard Le Fur.   

Abstract

Based on binding, functional, and pharmacological data, this study introduces SR147778 [5-(4-bromophenyl)-1-(2,4-dichloro-phenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide] as a highly potent, selective, and orally active antagonist for the CB1 receptor. This compound displays nanomolar affinity (Ki = 0.56 and 3.5 nM) for both the rat brain and human CB1 recombinant receptors, respectively. It has low affinity (Ki = 400 nM) for both the rat spleen and human CB2 receptors. Furthermore, it shows no affinity for any of the over 100 targets investigated (IC50 > 1 microM). In vitro, SR147778 antagonizes the inhibitory effects of CP 55,940 [(1R,3R,4R)-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]-4-(3-hydroxypropyl)cyclohexan-1-ol] on both the mouse vas deferens contractions (pA2 value = 8.1) and on forskolin-stimulated adenylyl cyclase activity in the U373 MG cell lines (pA2 value = 8.2) but not in Chinese hamster ovary (CHO) cells permanently expressing the human peripheral cannabinoid receptor (hCB2). SR147778 is able to block the mitogen-activated protein kinase activity induced by CP 55,940 in the CHO cell line expressing human brain cannabinoid receptor (IC50 = 9.6 nM) but was inactive in cells expressing hCB2. After oral administration, SR147778 displaced the ex vivo [3H]-CP 55,940 binding to mouse brain membranes (ED50 = 3.8 mg/kg) with a long duration of action, whereas it did not interact with the CB2 receptor expressed in the mouse spleen. Using different routes of administration, SR147778 (0.3-3 mg/kg) is shown to antagonize pharmacological effects (hypothermia, analgesia, and gastrointestinal transit) induced by R-(+)-(2,3-dihydro-5-methyl-3-[[4-morpholinyl]methyl] pyrol [1,2,3-de]-1,4-benzoxazin-6-yl)(1-naphthalenyl) methanone in mice. Finally, per se, SR147778 (0.3-10 mg/kg) is able to reduce ethanol or sucrose consumption in mice and rats and food intake in fasted and nondeprived rats.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15131245     DOI: 10.1124/jpet.104.067884

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  24 in total

1.  Are CB(1) Receptor Antagonists Nootropic or Cognitive Impairing Agents?

Authors:  Stephen A Varvel; Laura E Wise; Aron H Lichtman
Journal:  Drug Dev Res       Date:  2009-12-01       Impact factor: 4.360

2.  Effects of CB1 and CRF1 receptor antagonists on binge-like eating in rats with limited access to a sweet fat diet: lack of withdrawal-like responses.

Authors:  Sarah L Parylak; Pietro Cottone; Valentina Sabino; Kenner C Rice; Eric P Zorrilla
Journal:  Physiol Behav       Date:  2012-07-06

3.  Noladin ether, a putative endocannabinoid, enhances motivation to eat after acute systemic administration in rats.

Authors:  E K Jones; T C Kirkham
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

4.  The cannabinoid receptor agonist WIN 55,212-2 facilitates the extinction of contextual fear memory and spatial memory in rats.

Authors:  Fabrício A Pamplona; Rui D S Prediger; Pablo Pandolfo; Reinaldo N Takahashi
Journal:  Psychopharmacology (Berl)       Date:  2006-09-01       Impact factor: 4.530

Review 5.  The cannabinoid CB1 receptor antagonist, rimonabant, as a promising pharmacotherapy for alcohol dependence: preclinical evidence.

Authors:  Giancarlo Colombo; Alessandro Orrù; Paola Lai; Claudia Cabras; Paola Maccioni; Marina Rubio; Gian Luigi Gessa; Mauro A M Carai
Journal:  Mol Neurobiol       Date:  2007-07-03       Impact factor: 5.590

Review 6.  The endocannabinoid system and extinction learning.

Authors:  Beat Lutz
Journal:  Mol Neurobiol       Date:  2007-08-17       Impact factor: 5.590

7.  Pooled analysis of three randomized, double-blind, placebo controlled trials with rimonabant for smoking cessation.

Authors:  Jason D Robinson; Paul M Cinciripini; Maher Karam-Hage; Henri-Jean Aubin; Lowell C Dale; Raymond Niaura; Robert M Anthenelli
Journal:  Addict Biol       Date:  2017-04-21       Impact factor: 4.280

Review 8.  Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome.

Authors:  V Kiran Vemuri; David R Janero; Alexandros Makriyannis
Journal:  Physiol Behav       Date:  2007-11-21

9.  Investigation of endocannabinoid modulation of conditioned responding evoked by a nicotine CS and the Pavlovian stimulus effects of CP 55,940 in adult male rats.

Authors:  Jennifer E Murray; Nicole R Wells; George D Lyford; Rick A Bevins
Journal:  Psychopharmacology (Berl)       Date:  2009-06-04       Impact factor: 4.530

Review 10.  Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids.

Authors:  Dennis J Sholler; Marilyn A Huestis; Benjamin Amendolara; Ryan Vandrey; Ziva D Cooper
Journal:  Pharmacol Biochem Behav       Date:  2020-10-18       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.